rilonacept: Clinical Trials

14 trials of rilonacept, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 recruiting, 1 withdrawn. 14 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 12, Recruiting 1, Withdrawn 1
Phase 11Completed 1

Follow rilonacept: new trials by email Literature Review of rilonacept trials Research Report on rilonacept

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rilonacept in Subjects With Cardiac Sarcoidosis
Rilonacept - Cardiac Sarcoidosis
Phase 2RecruitingMayo Clinic602025-03-052026-08-20
A Pilot Study of KPL-914 in Recurrent Pericarditis
KPL-914 - Recurrent Pericarditis
Phase 2CompletedKiniksa Pharmaceuticals (UK), Ltd.262018-01-242021-05-27
Cold Contact Urticaria Treatment With Rilonacept
Rilonacept, Placebo - Cold Contact Urticaria
Phase 2CompletedCharite University, Berlin, Germany202015-01-012018-07-17
A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
Mycophenolate mofetil, Prednisolone, Rilonacept - Alcoholic Hepatitis
Phase 2CompletedSouthern California Institute for Research and Education42014-12-012025-06-12
Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Rilonacept - DIRA
Phase 2CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)62013-02-122017-10-16
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Rilonacept, Placebo - Chronic Kidney Disease, Cardiovascular Disease
Phase 2CompletedVA Office of Research and Development152013-01-012019-10-01
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Rilonacept, Placebo - Scleroderma, Systemic Sclerosis
Phase 1 / Phase 2CompletedBoston University242011-12-012018-05-01
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
rilonacept - Muckle-Wells Syndrome, Schnitzler Syndrome
Phase 2CompletedCharite University, Berlin, Germany102009-01-012012-05-31
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Rilonacept - Juvenile Idiopathic Arthritis
Phase 2CompletedMontefiore Medical Center712008-11-012015-12-11
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Rilonacept, Placebo - Familial Mediterranean Fever
Phase 2CompletedThe Cleveland Clinic142008-08-012013-02-11
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
Rilonacept, Placebo (for Rilonacept) - Gout
Phase 2CompletedRegeneron Pharmaceuticals832007-11-012017-05-02
Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Rilonacept, Placebo - Coronary Artery Disease, Atherosclerosis
Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)102006-12-012012-04-30
Interleukin-1 Trap to Treat Autoinflammatory Diseases
IL-1 Trap - Inflammation, Familial Mediterranean Fever
Phase 2CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)112004-10-012014-03-04
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Rilonacept - Chronic Kidney Disease, Anemia
Phase 2WithdrawnRegeneron Pharmaceuticals2011-04-19

Conditions studied

Inflammation (4)  ·  Cryopyrin-Associated Periodic Syndromes (2)  ·  Familial Mediterranean Fever (2)  ·  Renal Insufficiency, Chronic (2)  ·  Anemia (1)  ·  Arthritis, Juvenile (1)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Cold Urticaria (1)  ·  Coronary Artery Disease (1)  ·  Fever (1)  ·  Gout (1)  ·  Heart Failure (1)  ·  Hepatitis, Alcoholic (1)  ·  Myocarditis (1)

Sponsors

Charite University, Berlin, Germany (2)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2)  ·  Regeneron Pharmaceuticals (2)  ·  Boston University (1)  ·  Kiniksa Pharmaceuticals (UK), Ltd. (1)  ·  Mayo Clinic (1)  ·  Montefiore Medical Center (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Southern California Institute for Research and Education (1)  ·  The Cleveland Clinic (1)  ·  VA Office of Research and Development (1)

Countries

United States (12)  ·  Germany (2)

Top investigators

Adriana M Hung, MD MPH (1)  ·  Andrew Rosenbaum (1)  ·  Gary Swergold, MD, PhD (1)  ·  Gina A Montealegre, M.D. (1)  ·  Karoline Krause, MD (1)  ·  Marcus Maurer, MD (1)  ·  Norman T. Ilowite, MD (1)  ·  Philip J Hashkes, MD, MSc (1)  ·  Richard O Cannon, MD (1)  ·  Robert W Simms, MD (1)  ·  Shirletta King-Davis (1)  ·  Timothy R. Morgan, MD (1)

Results publications

PMID 18668591, PMID 21372003, PMID 22223180, PMID 22583335, PMID 23070486, PMID 24833067, PMID 25147819, PMID 28814674, PMID 30277862, PMID 33229362, PMID 33882846, PMID 36973954

NIH funding

268200700015C-2-0-0 (1), U01AA021886 (1)